Blood levels of brain growth protein after oral esketamine in hard-to-treat depression: Results from a placebo-controlled trial

Declaration of competing interest RS has received research funding for two randomized clinical trials with generic PO esketamine from the Netherlands Organisation for Health Research & Development and the National Health Care Institute, a speaker's fee and an investigator-initiated research grant from Janssen Pharmaceuticals, and consultancy fees from Clexio biosciences, GH Research, Beckley PsyTech, and QPS. Funding for the present study received by JvD and RS comprises a public-private partnership that includes co-funding by pharmacological companies that hold licences to or are developing pharmacological treatment for depression including Johnson & Johnson, Compass Pathways, and Novartis Pharma. JV has received a speaker's fee from Janssen Pharmaceuticals, outside the submitted work. All other authors declare no competing interests.